| Market Capitalization (Millions $) |
0 |
| Shares
Outstanding (Millions) |
7 |
| Employees |
62 |
| Revenues (TTM) (Millions $) |
60 |
| Net Income (TTM) (Millions $) |
-48 |
| Cash Flow (TTM) (Millions $) |
3 |
| Capital Exp. (TTM) (Millions $) |
0 |
Molecular Templates Inc
Molecular Templates Inc. is a clinical-stage biopharmaceutical company that is focused on the discovery, development, and commercialization of targeted biologic therapeutics. The company is based in Austin, Texas and was founded in 2016 by Eric Poma, a molecular biology professor at the University of Texas.
Molecular Templates has developed a proprietary platform technology known as Engineered Toxin Bodies (ETBs) that is designed to combine the targeting ability of an antibody with the cytotoxicity of a bacterial toxin. These ETBs are able to selectively target and destroy cancer cells while sparing healthy cells, making them an attractive option for cancer therapy.
The company has several ETB-based product candidates in clinical development for the treatment of various types of cancer, including Non-Hodgkin's Lymphoma (NHL), multiple myeloma, and solid tumors. One of its leading product candidates, MT-3724, is an ETB targeting CD20, a protein that is overexpressed on the surface of NHL cells.
Molecular Templates has also developed a bi-specific ETB technology that enables specific targeting of cancer cells with two different binding sites, potentially increasing the therapeutic benefit. The company is further exploring the potential of its ETB platform technology to develop therapeutics for the treatment of other diseases besides cancer.
In addition to its product pipeline, Molecular Templates has established collaborations with several companies and academic institutions to further advance its technology and platform. The company has also secured several patents related to its ETB platform technology.
Molecular Templates is led by a team of experienced executives and scientists who have a strong track record in biopharmaceutical drug discovery and development. The company is well-funded with over $180 million in cash and investments as of June 2021, which provides it with the financial resources to advance its product pipeline and research programs.
Overall, Molecular Templates is a promising biopharmaceutical company that is developing innovative and targeted therapies for the treatment of cancer and other diseases. Its unique ETB platform technology has the potential to transform the field of cancer therapeutics and improve patient outcomes.
Company Address: 9301 Amberglen Blvd Austin 78729 TX
Company Phone Number: 869-1555 Stock Exchange / Ticker: NASDAQ MTEM
|
0.000%
1.53% 